

Atsushi Ogata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9069463/publications.pdf>

Version: 2024-02-01

76
papers

3,317
citations

136950

32
h-index

149698

56
g-index

78
all docs

78
docs citations

78
times ranked

4499
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid attenuation of anti-SARS-CoV-2 antibodies in patients with musculoskeletal diseases in whom intensive immunosuppressive therapies were reinitiated after COVID-19: comment on the article by Curtis et al. <i>Arthritis and Rheumatology</i> , 2022, 74, 726-728.	5.6	1
2	Increased levels of plasma nucleotides in patients with rheumatoid arthritis. <i>International Immunology</i> , 2021, 33, 119-124.	4.0	11
3	Autoimmune myelofibrosis associated with systemic lupus erythematosus: a case report. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 28-33.	0.7	3
4	Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 103-111.	0.9	145
5	Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 639-648.	5.0	4
6	Anti-receptor activator of nuclear factor κ B ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis. <i>International Immunology</i> , 2019, 31, 277-285.	4.0	9
7	IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. <i>Modern Rheumatology</i> , 2019, 29, 258-267.	1.8	134
8	Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. <i>Modern Rheumatology</i> , 2019, 29, 767-774.	1.8	10
9	A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. <i>Modern Rheumatology</i> , 2018, 28, 76-84.	1.8	17
10	Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e56-e56.	0.9	4
11	Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1078-1085.	0.9	76
12	The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0162306.	2.5	70
13	Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1354-1362.	3.4	26
14	Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications. <i>Arthritis and Rheumatology</i> , 2015, 67, 1481-1490.	5.6	79
15	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. <i>Journal of Rheumatology</i> , 2015, 42, 799-809.	2.0	39
16	Brief Report: Leucine-Rich Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2056-2060.	5.6	71
17	Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis. <i>Therapeutic Delivery</i> , 2015, 6, 283-295.	2.2	11
18	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. <i>Modern Rheumatology</i> , 2015, 25, 134-137.	1.8	26

#	ARTICLE	IF	CITATIONS
19	Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. <i>Biologics: Targets and Therapy</i> , 2014, 8, 141.	3.2	45
20	Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 344-354.	3.4	118
21	Amelioration of Small Bowel Injury by Switching from Nonselective Nonsteroidal Anti-Inflammatory Drugs to Celecoxib in Rheumatoid Arthritis Patients: A Pilot Study. <i>Digestion</i> , 2014, 89, 124-132.	2.3	11
22	A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. <i>Seminars in Immunology</i> , 2014, 26, 88-96.	5.6	144
23	Clinical characteristics and risk factors for <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. <i>Modern Rheumatology</i> , 2013, 23, 1085-93.	1.8	18
24	Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 253-259.	1.1	33
25	A point mutation in Semaphorin 4A associates with defective endosomal sorting and causes retinal degeneration. <i>Nature Communications</i> , 2013, 4, 1406.	12.8	21
26	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. <i>Modern Rheumatology</i> , 2013, , 1.	1.8	12
27	DNA Damage in Rheumatoid Arthritis: An Age-Dependent Increase in the Lipid Peroxidation-Derived DNA Adduct, Heptanone-Ethene-2-Deoxycytidine. <i>Autoimmune Diseases</i> , 2013, 2013, 1-8.	0.6	9
28	Lectin-based Immunoassay for Aberrant IgG Glycosylation as the Biomarker for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 321-331.	1.9	33
29	Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S9282.	0.4	12
30	Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2012, 5, CMAMD.S7371.	1.2	64
31	A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Modern Rheumatology</i> , 2012, 22, 298-302.	1.8	97
32	Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN- β Therapy in Multiple Sclerosis. <i>Journal of Immunology</i> , 2012, 188, 4858-4865.	0.8	64
33	Pathological Role of Interleukin-6 in Psoriatic Arthritis. <i>Arthritis</i> , 2012, 2012, 1-6.	2.0	29
34	Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-14.	1.6	40
35	Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis. <i>World Allergy Organization Journal</i> , 2012, 5, S181.	3.5	0
36	Clinical Effects of Tocilizumab, a Humanized Anti-interleukin-6 Receptor Antibody, on Patients with Autoimmune and Allergic Diseases. <i>World Allergy Organization Journal</i> , 2012, 5, S111.	3.5	0

#	ARTICLE	IF	CITATIONS
37	Rhumatisme psoriasique chez deux patients en Ã©chec de traitement par le tocilizumab. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 168-170.	0.0	0
38	Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine, 2012, 79, 85-87.	1.6	58
39	A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Modern Rheumatology, 2012, 22, 298-302.	1.8	64
40	Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review. Current Rheumatology Reviews, 2012, 8, 209-226.	0.8	4
41	Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Modern Rheumatology, 2011, 21, 436-439.	1.8	22
42	Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders. Drug Development Research, 2011, 72, 717-732.	2.9	1
43	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Modern Rheumatology, 2011, 21, 420-422.	1.8	15
44	Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab: Figure 1. Annals of the Rheumatic Diseases, 2011, 70, 1164-1165.	0.9	79
45	Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology, 2011, 50, 1344-1346.	1.9	115
46	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Modern Rheumatology, 2011, 21, 420-422.	1.8	12
47	Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Modern Rheumatology, 2011, 21, 436-439.	1.8	23
48	The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology, 2010, 49, 2408-2412.	1.9	177
49	Tocilizumab for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2010, 6, 843-854.	3.0	70
50	Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology, 2010, 49, 824-826.	1.9	21
51	iTRAQ-based proteomic identification of leucine-rich Å-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Annals of the Rheumatic Diseases, 2010, 69, 770-774.	0.9	179
52	Minimal influence of tocilizumab on IFN-Î³ synthesis by tuberculosis antigens. Modern Rheumatology, 2010, 20, 130-133.	1.8	25
53	Minimal influence of tocilizumab on IFN-Î³ synthesis by tuberculosis antigens. Modern Rheumatology, 2010, 20, 130-133.	1.8	20
54	Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial. International Archives of Allergy and Immunology, 2009, 149, 359-368.	2.1	41

#	ARTICLE	IF	CITATIONS
55	Preventative Effect of a Flavonoid, Enzymatically Modified Isoquercitrin on Ocular Symptoms of Japanese Cedar Pollinosis. <i>Allergology International</i> , 2009, 58, 373-382.	3.3	40
56	Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2009, 76, 105-107.	1.6	13
57	Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Arthritis and Rheumatism</i> , 2009, 61, 1762-1764.	6.7	69
58	Cirrhose biliaire primitive associée à une polyarthrite rhumatoïde améliorées par l'etanercept. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2009, 76, 113-115.	0.0	0
59	Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1235-1236.	0.9	72
60	Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. <i>Modern Rheumatology</i> , 2009, 19, 522-529.	1.8	16
61	What kind of durometer is best suited for the assessment of skin disease in systemic sclerosis? Comment on the article by Kissin et al. <i>Arthritis and Rheumatism</i> , 2008, 59, 601-601.	6.7	4
62	Flavonoids and Related Compounds as Anti-Allergic Substances. <i>Allergology International</i> , 2007, 56, 113-123.	3.3	277
63	Flavonoids and related compounds as anti-allergic substances. <i>World Allergy Organization Journal</i> , 2007, &NA;, S148.	3.5	0
64	Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. <i>International Journal of Hematology</i> , 2007, 86, 414-417.	1.6	55
65	Luteolin, a flavonoid, inhibits AP-1 activation by basophils. <i>Biochemical and Biophysical Research Communications</i> , 2006, 340, 1-7.	2.1	72
66	IL-18 gene polymorphisms affect IL-18 production capability by monocytes. <i>Biochemical and Biophysical Research Communications</i> , 2006, 342, 1413-1416.	2.1	92
67	Cevimeline hydrochloride improved cholinergic dysfunction in a patient with pure autonomic failure. <i>Journal of Neurology</i> , 2006, 253, 119-120.	3.6	1
68	Luteolin, a Flavonoid, Inhibits CD40 Ligand Expression by Activated Human Basophils. <i>International Archives of Allergy and Immunology</i> , 2006, 140, 150-156.	2.1	30
69	Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. <i>Journal of Bone and Mineral Metabolism</i> , 2005, 23, 48-52.	2.7	11
70	Increased serum interleukin-18 in a patient with systemic lupus erythematosus and T-cell large granular lymphocytic leukemia. <i>Modern Rheumatology</i> , 2004, 14, 267-270.	1.8	15
71	Increased serum interleukin-18 in a patient with systemic lupus erythematosus and T-cell large granular lymphocytic leukemia. <i>Modern Rheumatology</i> , 2004, 14, 267-70.	1.8	10
72	Interleukin 18 and hepatocyte growth factor in fulminant hepatic failure of adult onset Still's disease. <i>Journal of Rheumatology</i> , 2003, 30, 1093-6.	2.0	29

#	ARTICLE	IF	CITATIONS
73	Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease. <i>Journal of Bone and Mineral Metabolism</i> , 2002, 20, 240-242.	2.7	0
74	The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. <i>Immunology</i> , 2001, 103, 310-318.	4.4	57
75	Successful Treatment of a Patient with Febrile, Lobular Panniculitis (Weber-Christian Disease) with Oral Cyclosporin A. Implications for Pathogenesis and Therapy.. <i>Internal Medicine</i> , 1999, 38, 612-614.	0.7	36
76	Immunogenicity of Subcutaneous and Intravenous Tocilizumab as Monotherapy or in Combination with Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis. <i>Rheumatology</i> , 0, , .	1.9	0